BioSpace News Archive

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, provided a corporate update.

The White House announced today that the US has shipped 400 million doses of COVID-19 vaccines around the world, a milestone that AIDS Healthcare Foundation (AHF) described as commendable but still far short of what is needed to vaccinate our world.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s prostate-specific membrane antigen (PSMA) targeting ‘ProstACT’ therapeutic program, which is exploring TLX591 in areas of unmet medical need across the full prostate cancer treatment journey.

Trial lawyers with the Lanier Law Firm have filed a $10 million lawsuit against Johnson & Johnson, its Janssen Pharmaceuticals subsidiary, and other parties on behalf of a New Hampshire woman who suffered eye damage after long-term use of the drug Elmiron, prescribed for bladder pain

IQVIA (NYSE:IQV) today announced the appointment of Sheila A. Stamps to its board of directors, effective today.

SQI Diagnostics Inc. (‘SQI” or the “Company”) (TSXV: SQD) (OTCQB: SQIDF), today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2021.

Galvani Bioelectronics, today announced that the first patient with Rheumatoid Arthritis (RA) has been treated through stimulation of the splenic nerve using its novel bioelectronics platform.

Leonhardt Ventures LLC, a Mission Viejo, California based company via it’s innovation and startup launch accelerator Leonhardt’s Launchpads, announced today that it has begun an active research program to combine its patent-pending klotho expression bioelectric stimulation technologies with newly acquired klotho expressing mesenchymal stem cell technology.

Agilent Technologies Inc. recently signed a Research Collaboration Agreement with the Singapore Institute of Food and Biotechnology Innovation outlining their collaboration on developing food research knowledge advancement over the next two years.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that David E. Anderson, Ph.D, VBI’s Chief Scientific Officer, will present an overview of VBI-1901, the Company’s cancer immunotherapeutic for the treatment of glioblastoma (GBM), at B. Riley’s Oncology Investor Conference.